Liraglutide, an analog of glucagon-like peptide-1 that may improve β-cell mass and function, was combined with an anti-IL-21 neutralizing mAb in recent-onset T1D patients [115], leading to a moderate preservation of β cells. The gene discussed is IL21; the disease is type 1 diabetes mellitus.